US medical device studies

How to run a medical device clinical trial in the US

Before you sign a US site, establish what evidence is missing, which approvals apply and how many eligible patients the site can realistically enroll.

Do you need a US cohort?

Start with the intended use, device version, patient population and claim you want FDA to assess. FDA can accept clinical data collected outside the US. For studies begun on or after February 21, 2019, review the FDA requirements for good clinical practice and the records that show how the study was conducted.

Device and indication

Did the earlier study evaluate the version, intended users and use conditions proposed for the US label? Document material changes.

Patients and practice

Could disease severity, operator training, the comparator or usual care change how the results apply to US patients?

Outcomes and records

Can you trace the primary endpoint to source records and account for missing follow-up, protocol changes and adverse-event definitions?

Record each gap and how you propose to close it. A reanalysis may answer one question. A targeted US cohort may answer another. If the remaining gap changes the study design, take a specific proposal to FDA before committing sites.

Which IDE and IRB reviews apply?

Assess the proposed use of the device and the procedures participants will undergo. Check the investigational device exemption (IDE) criteria in 21 CFR 812.2(c). If Part 812 applies, document the sponsor’s risk assessment. The institutional review board (IRB) reviews that assessment unless FDA has already made the determination. FDA has final authority.

Study routes and start-up requirements
Study routeBefore enrollment
IDE-exempt investigationIdentify the specific exemption and document why its conditions are met. Assess IRB review and informed-consent obligations separately.
Nonsignificant risk (NSR)When the IRB agrees with the NSR determination and approves the investigation, follow abbreviated IDE requirements, including labeling, consent, monitoring, records and reporting. A separate FDA IDE application is generally unnecessary.
Significant risk (SR)Obtain FDA IDE authorization and IRB approval before starting. Review any FDA conditions for limits on enrollment, participating sites or study activities.

FDA’s 30-calendar-day review. An original IDE is considered approved 30 days after FDA receives it unless FDA communicates a different decision within that period. FDA can approve earlier, approve with conditions or disapprove. Build the opening date around the actual decision, IRB approval and site readiness.

Manufacturers based outside the US. A foreign company submitting an IDE needs a US agent who acts as sponsor and assumes the IDE sponsor’s responsibilities. Agree who will handle monitoring, investigator oversight, records and reports before submission.

Match the study design to the decision

An early feasibility study can provide initial clinical evidence of device function and safety. For a pivotal study, define the intended claim, population, primary endpoint, time point and analysis. Specify a comparator or performance goal where appropriate. Assess SR or NSR separately from the development stage.

When two designs imply different study sizes or follow-up periods, use an FDA Pre-Submission to ask a focused question. Include both options, your preferred design and its rationale. A Pre-Submission provides feedback. Enrollment follows the study’s applicable approval route.

A question to take to FDA

“We propose measuring device performance at six months and collecting safety data through twelve months. Given the timing of events in our feasibility study, does FDA agree with this endpoint and follow-up?”

Attach the event data and explain how longer follow-up would change the design.

How many patients could one site enroll?

Ask the investigator and coordinator to review screening records from a defined recent period. Apply the protocol criteria, then account for competing studies, operator availability and capacity for follow-up.

Illustrative monthly forecast for one site
  1. 24relevant procedures each month
  2. 12patients meet the criteria in a record review
  3. 6can be approached with current clinic capacity
  4. 3participants enroll if half of those approached consent

Record the dates, denominator, trained operator schedule and coordinator capacity. Repeat the calculation at each site. A smaller center can out-recruit a busier one if more eligible patients can be approached and followed.

Build the budget and the first-site timeline together

Separate start-up and closeout fees from per-participant and per-visit charges. Cost screen failures, unscheduled visits, monitoring, data management, specialist assessments and device logistics. Agree which activities the sponsor funds.

If Medicare coverage is relevant, verify study coverage and ask the site’s billing team to allocate the costs.

What one extra assessment costs

At an illustrative rate of $450 per participant, one additional sponsor-funded assessment for 60 participants adds $27,000 before overhead or extra monitoring. Replace the example rate with the site’s quote.

Illustrative first-site timeline

Run regulatory review, contract negotiation, training and system access in parallel. Site activation and first enrollment have separate dates.

  1. Week 5Required regulatory and ethics approvals are in place.
  2. Week 8The site signs its contract and confirms the budget.
  3. Week 9Training is complete. The sponsor releases the site to recruit.
  4. Week 11The first eligible participant enrolls.

First-site release checklist

Use the boxes during your start-up review. Assign an owner to each item and keep the supporting record in the study file.

First-site readiness checks

Request a US clinical trial proposal

Share the device and intended use, the decision your study must support, your target date and the activities you want ECLEVAR to price. Include any site or enrollment assumptions and the question still open after FDA feedback.